ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23.5 TWD -0.63% Market Closed
Market Cap: 18.6B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ScinoPharm Taiwan Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Depreciation & Amortization
NT$471.6m
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
0%
Y
YungShin Global Holding Corp
TWSE:3705
Depreciation & Amortization
NT$284.5m
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
Formosa Laboratories Inc
TWSE:4746
Depreciation & Amortization
NT$505.8m
CAGR 3-Years
3%
CAGR 5-Years
8%
CAGR 10-Years
12%
S
SCI Pharmtech Inc
TWSE:4119
Depreciation & Amortization
NT$191.9m
CAGR 3-Years
27%
CAGR 5-Years
7%
CAGR 10-Years
4%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Depreciation & Amortization
NT$1.2B
CAGR 3-Years
18%
CAGR 5-Years
21%
CAGR 10-Years
27%
Standard Chem & Pharm Co Ltd
TWSE:1720
Depreciation & Amortization
NT$382.1m
CAGR 3-Years
19%
CAGR 5-Years
13%
CAGR 10-Years
10%
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
18.6B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
16.51 TWD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is ScinoPharm Taiwan Ltd's Depreciation & Amortization?
Depreciation & Amortization
471.6m TWD

Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Depreciation & Amortization amounts to 471.6m TWD.

What is ScinoPharm Taiwan Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
0%

Over the last year, the Depreciation & Amortization growth was 2%. The average annual Depreciation & Amortization growth rates for ScinoPharm Taiwan Ltd have been 7% over the past three years , 3% over the past five years .

Back to Top